Role of Dienogest in Endometriosis in Young Women.

Abstract

Endometriosis associated pelvic pain (EAPP) is the most common complaint of patients with endometriosis. Nearly, 70% of females with endometriosis present with EAPP while endometriomas are found in 17-44% of patients. A short-term single centre study was carried out in 56 patients in the age group of 15-35years with complaints of pain and diagnosed as endometriosis either by imaging studies and/or by laparoscopy was given dienogest 2mg OD, and effect of treatment was seen as improvement of pain score over a period of 3months. The effect of dienogest was also seen on size of endometrioma. Patients were followed up at 1 and 3months. Out of 56 patients, 38 (67.8%) patients reported their pain relief within 2-5days after starting dienogest. Out of 41 patients (73%) who had severe pain at enrollment, only 1 patient (1.79%) complained of severe pain at the end of 1month with dienogest. Successful reduction in endometriotic cyst size (>50%) was seen in 3 patients (5.3%) at the end of 1month with dienogest. Out of 56 patients, 41 patients (73.2%) had significant pain relief (>30%) at three months of treatment. At the end of 3months, seven patients (12.5%) had significant cyst size reduction (>50%) with dienogest. No major side effects were noted. Dienogest is well tolerated drug for endometriosis showing significant relief of pain. However, it was seen that though endometriomas did not grow during treatment, significant regression was uncommon.